The Stool Softeners Market to cling to the digitization

The Stool Softeners Market is bound to witness a robust CAGR going forward. The present scenario is that of prediction of the course of treatment based on data analytics. Technology has been dominating in the form of IoMT (Internet-of-Medical-Things), AI (Artificial Intelligence), cloud computing, predictive analytics, and what not? With the proven advantage of the reduction in casualties and real-time access to the history of patients, and not to forget – remote monitoring, the healthcare industry is there to upturn.

According to the American Gastroenterological Association, the prevalence of constipation is 16% in all adults and about 33.5% is attributed to population older than 60 years.

The demand for stool softeners is largely associated with the increasing incidence of constipation. Geriatric patients present a widespread presence of cases of constipation as compared to the younger population. This is due to the lack of physical activity, lack of proper diet, consumption of low-fiber foods, presence of illness and the use of prescribed drugs, which leads to a rise in demand of stool softeners in this population group.

The prevalence rate of constipation is reported to be between 11%-38%, according to the National Institute for Clinical Excellence. Constipation due to pregnancy, and menopausal cases with fluctuations of hormonal levels has also boosted the use of stool softeners globally.

Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/32579

Furthermore, eating disorders sedentary lifestyle, stress, inadequate fluid intake and endocrine or metabolic disorders among many other factors are responsible for the uptake of stool softeners to administer relief over a short-term phase of use.

The most critical augmentative factor in the growth of demand in stool softeners is the increasing prevalence of ailments such as diabetes, anorectal disorders and hypothyroidism. According to a review in the Neurogastroenterology and Motility Journal, the effect on autonomic nerves of the colon due to changes in the vagus nerve in patients with diabetes mellitus results in constipation.

This factor has enhanced the growth of administration of stool softeners for patients with constipation associated with diabetes and other inadequacies including neurological disorders.

North America dominates the stool softeners market due to the increasingly sedentary lifestyle as well as unbalanced or poor diet-related factors. Increasing prevalence of diabetes and associated cases of constipation has led to a significant increase in the usage of stool softeners.

According to the CDC- National Diabetes Statistics Report for 2020, in the U.S., over 10.5% of the population have been reported to have diagnosed with diabetes. A large presence of healthcare and pharmaceutical players in this region such as Gemini Pharmaceuticals, has further augmented the growth of adoption of stool softeners.

The Regulatory Cooperation Initiative (RCI) Over-the-Counter (OTC) Products in Canada considered labelling standards for over the counter Docusate as stool softeners, enhancing the uptake for occasional relief from constipation and digestive abnormalities.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

The growth of stool softeners in Europe is largely attributed to the increasing presence of chronic constipation in the region. Europe reports over 17% of prevalence rate of chronic constipation, as per the Neurogastroenterology and Motility Journal. This rate is reflected due to the growing geriatric population and higher consumption of medicines, which drive the high growth rate of stool softeners in this region.

The key companies operating in manufacturing and supply of stool softeners include,

AstraZeneca plc
Teva Pharmaceutical Industries Ltd.
Bayer AG
Abbott Laboratories
Aristo Pharmaceuticals Ltd.
Mallinckrodt Plc.
Unipex
Hunan Warant Chiral Pharmaceutical
Boehringer Ingelheim GmbH
Takeda Pharmaceutical Company Ltd
Raptakos Brett & Co. Ltd.
Mylan N.V.
GlaxoSmithKline plc
Stadmed Pvt. Ltd.
Purdue Pharma L.P.

The key players adopt strategic acquisitions to fuel R&D activity resulting in new product innovations. For instance, Mallinckrodt plc acquired Sucampo Pharmaceuticals, Inc. in 2018 and gained rights to its commercial and developmental assets.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/32579

Key Segments

By Form

Liquid
Softgel Capsule
Enema

By Mode of Administration

Oral
Rectal

By Drug Type

Generic
Branded

By Availability

Over the Counter
Prescription

By End User

Hospitals
Clinics
Research Institutes

By Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa

About us: Persistence Market Research

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Lake Shore Gazette

Leave a Reply Cancel reply